Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on Safety, Tolerability, and Potential Outcomes in Adult Patients With ABPA

NCT05667662 is registered in ClinicalTrials.gov with Pulmatrix Inc. as lead sponsor.

NCT NCT05667662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05667662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Effect of Dose and Duration of Treatment of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) on Safety, Tolerability, and Potential Outcomes in Adult Patients With ABPA
Lead sponsor
Pulmatrix Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 1, 2023
Completion date
February 27, 2024
Enrollment
8 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

abpa